PMID- 29602796
OWN - NLM
STAT- MEDLINE
DCOM- 20180928
LR  - 20181001
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 94
IP  - 1112
DP  - 2018 Jun
TI  - Survival rate and predictors of mortality in patients hospitalised with heart 
      failure: a cohort study on the data of Persian registry of cardiovascular disease 
      (PROVE).
PG  - 318-324
LID - 10.1136/postgradmedj-2018-135550 [doi]
AB  - OBJECTIVES: Heart failure (HF) has a high rate of hospitalisation and mortality. 
      We examined its risk factors, survival rate and the predictors. METHODS: In this 
      prospective cohort study, demographic, clinical and treatment data of 1223 
      patients hospitalised with HF were extracted from the Persian Registry Of cardio 
      Vascular diseasE (PROVE)/HF registry. Survival rate and HR and their association 
      with other variables were assessed. RESULTS: 835 (68.3%) were censored, while 388 
      (31.7%) patients were deceased. Mean age and frequency of hypotension during 
      hospitalisation, tachycardia, pulmonary hypertension and anaemia, hyponatremia, 
      heart valve disease and renal disease of the deceased patients was significantly 
      higher than censored patients (15.2vs6.1%, 51.1vs40.1%, 24.4vs16.7%, 39.0vs31.8%, 
      respectively, p<0.05). ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) 
      (89.8%vs82.1%, respectively) and beta blocker (BB) (81.1%vs75.5%, respectively) 
      were higher in follow-up in the censored group (p<0.001 and 0.02, respectively). 
      Crude Cox regression analysis identified age, tachycardia, hypotension, anaemia, 
      pulmonary hypertension and heart valve disease as predictors of mortality (HR >1) 
      and using ACEI/ARB and BB as predictors of life (HR <1, p<0.05). After 
      adjustment, all variables lost their significance, except BB (HR 0.63, p=0.03) 
      and tachycardia (HR 1.74, p=0.01) and New York Heart Association (NYHA) class IV 
      (HR 1.90, p=0.04) became significant predictors. CONCLUSIONS: We found a high 
      mortality rate (31.7%). As NYHA class IV and tachycardia were significant 
      predictors of mortality after adjustment, an effective measure can be treatment 
      of underlying diseases, which deteriorate patients' conditions. Monitoring of 
      medications for at-risk group, especially BB that predicts life, is important.
CI  - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of 
      the article) 2018. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Givi, Mahshid
AU  - Givi M
AD  - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Shafie, Davood
AU  - Shafie D
AD  - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Nouri, Fatemeh
AU  - Nouri F
AD  - Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Garakyaraghi, Mohammad
AU  - Garakyaraghi M
AD  - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Yadegarfar, Ghasem
AU  - Yadegarfar G
AD  - Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Sarrafzadegan, Nizal
AU  - Sarrafzadegan N
AD  - Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
AD  - Faculty of Medicine, School of Population and Public Health, University of 
      British Columbia, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180330
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Female
MH  - Heart Failure/*mortality/therapy
MH  - Hospitalization
MH  - Humans
MH  - Iran/epidemiology
MH  - Male
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - Survival Rate
OTO - NOTNLM
OT  - heart failure
OT  - kaplan-meier estimate
OT  - risk factors
OT  - survival rate
COIS- Competing interests: None declared.
EDAT- 2018/04/01 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/04/01 06:00
PHST- 2018/01/04 00:00 [received]
PHST- 2018/03/06 00:00 [revised]
PHST- 2018/03/14 00:00 [accepted]
PHST- 2018/04/01 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/04/01 06:00 [entrez]
AID - postgradmedj-2018-135550 [pii]
AID - 10.1136/postgradmedj-2018-135550 [doi]
PST - ppublish
SO  - Postgrad Med J. 2018 Jun;94(1112):318-324. doi: 10.1136/postgradmedj-2018-135550. 
      Epub 2018 Mar 30.